ImmunoVaccine Technologies

Contact
immunovaccine.com
+1902492-1819

ImmunoVaccine Technologies Inc. (IVT)

1819 Granville Street, Suite 303
B3J 3R1 Halifax
Canada
+1902492-1819
immunovaccine.com
Contact
Profile News
Contact

About ImmunoVaccine Technologies

ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases.

Read more about ImmunoVaccine Technologies
Facts about ImmunoVaccine Technologies
  • Focus : Manufacturer
  • Industry : Pharma

News about ImmunoVaccine Technologies

ImmunoVaccine Technologies

30-Sep-2009 | people

ImmunoVaccine Technologies Appoints New CFO

Immunovaccine Technologies (IVT) announced that it has appointed Gary Dodge, CA, as Chief Financial Officer. Reporting to president and CEO Dr. Randal ...

Read news
ImmunoVaccine Technologies

16-Jul-2009 | business & finance

ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens

ImmunoVaccine Technologies Inc. (IVT) has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery ...

Read news
ImmunoVaccine Technologies

06-Oct-2008 | research and development

ImmunoVaccine Technologies DepoVax Shows Positive Results for Cancer and Infectious Diseases

ImmunoVaccine Technologies (IVT) patented depot vaccine formulation, DepoVax(TM) is showing positive pre-clinical results, with single-dose efficacy ...

Read news
ImmunoVaccine Technologies

07-Aug-2008 | research and development

ImmunoVaccine Technologies Broadens Its Patent Protection to Japan

ImmunoVaccine Technologies Inc. (IVT) announced receipt of patent approval from the Japanese Patent Office for its vaccine platform. The specific patent, ...

Read news
ImmunoVaccine Technologies

12-Dec-2007 | business & finance

ImmunoVaccine Technologies Inc. to Acquire Immunotope Inc.

ImmunoVaccine Technologies Inc. (IVT) has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology ...

Read news
ImmunoVaccine Technologies

03-Dec-2007 | research and development

ImmunoVaccine Technologies Inc. Completes Scale-Up of VacciMax to Commercially Relevant Scale

ImmunoVaccine Technologies Inc. (IVT) announced that it has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax(R). This ...

Read news
ImmunoVaccine Technologies

25-Aug-2006 | business & finance

Pharmexa grants PADRE license to ImmunoVaccine Technologies Inc.

Pharmexa has entered into a license agreement with ImmunoVaccine Technologies Inc. (IVT) of Halifax, Nova Scotia for the use of PADRE® immunostimulatory ...

Read news
ImmunoVaccine Technologies

29-Sep-2005 | research and development

ImmunoVaccine Technologies Receives European Patent Allowance

ImmunoVaccine Technologies Inc. (IVT) announced that it has received a patent allowance from the European patent office for their patent application ...

Read news
Show more news about ImmunoVaccine Technologies

Here you will find ImmunoVaccine Technologies Inc. (IVT)